SA520412289B1 - مركبات مثبط الهدف الميكانيكي للراباميسين - Google Patents
مركبات مثبط الهدف الميكانيكي للراباميسينInfo
- Publication number
- SA520412289B1 SA520412289B1 SA520412289A SA520412289A SA520412289B1 SA 520412289 B1 SA520412289 B1 SA 520412289B1 SA 520412289 A SA520412289 A SA 520412289A SA 520412289 A SA520412289 A SA 520412289A SA 520412289 B1 SA520412289 B1 SA 520412289B1
- Authority
- SA
- Saudi Arabia
- Prior art keywords
- rapamycin
- inhibitor compounds
- mechanistic target
- present
- target
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title abstract 4
- 239000003112 inhibitor Substances 0.000 title abstract 4
- 102000013530 TOR Serine-Threonine Kinases Human genes 0.000 title abstract 3
- 108010065917 TOR Serine-Threonine Kinases Proteins 0.000 title abstract 3
- 239000000203 mixture Substances 0.000 abstract 2
- ZAHRKKWIAAJSAO-UHFFFAOYSA-N rapamycin Natural products COCC(O)C(=C/C(C)C(=O)CC(OC(=O)C1CCCCN1C(=O)C(=O)C2(O)OC(CC(OC)C(=CC=CC=CC(C)CC(C)C(=O)C)C)CCC2C)C(C)CC3CCC(O)C(C3)OC)C ZAHRKKWIAAJSAO-UHFFFAOYSA-N 0.000 abstract 2
- QFJCIRLUMZQUOT-HPLJOQBZSA-N sirolimus Chemical compound C1C[C@@H](O)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 QFJCIRLUMZQUOT-HPLJOQBZSA-N 0.000 abstract 2
- 229960002930 sirolimus Drugs 0.000 abstract 2
- 239000003814 drug Substances 0.000 abstract 1
- 238000009472 formulation Methods 0.000 abstract 1
- 238000004519 manufacturing process Methods 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/10—Anti-acne agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
- C07D487/20—Spiro-condensed systems
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Dermatology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Abstract
يتعلق الاختراع الحالي بمركبات مثبط inhibitor compounds الهدف الميكانيكي للراباميسين mechanistic target of rapamycin (mTOR) جديدة. ويتسم الاختراع الحالي بأن مركبات مثبط الهدف الميكانيكي للراباميسين لها الصيغة العامة (I). كما يتعلق الاختراع الحالي أيضا بتركيبات تشتمل على مركبات مثبط الهدف الميكانيكي للراباميسين المذكورة، وطرق لإنتاجها واستخدامها في تركيبات كعقاقير طبية. شكل1
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
FR1771402A FR3075795A1 (fr) | 2017-12-21 | 2017-12-21 | Nouveaux composes inhibiteurs de mtor |
PCT/EP2018/086074 WO2019122065A1 (fr) | 2017-12-21 | 2018-12-20 | Composes inhibiteurs de mtor |
Publications (1)
Publication Number | Publication Date |
---|---|
SA520412289B1 true SA520412289B1 (ar) | 2022-07-28 |
Family
ID=62017455
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SA520412289A SA520412289B1 (ar) | 2017-12-21 | 2020-06-21 | مركبات مثبط الهدف الميكانيكي للراباميسين |
Country Status (16)
Country | Link |
---|---|
US (1) | US11518767B2 (ar) |
EP (1) | EP3727390B1 (ar) |
JP (1) | JP2021506917A (ar) |
KR (1) | KR20200103032A (ar) |
CN (1) | CN111918654A (ar) |
AU (1) | AU2018392761B2 (ar) |
BR (1) | BR112020012201A2 (ar) |
CA (1) | CA3086243A1 (ar) |
CL (1) | CL2020001686A1 (ar) |
FR (1) | FR3075795A1 (ar) |
IL (1) | IL275531B2 (ar) |
MX (1) | MX2020006436A (ar) |
RU (1) | RU2020123899A (ar) |
SA (1) | SA520412289B1 (ar) |
SG (1) | SG11202005868XA (ar) |
WO (1) | WO2019122065A1 (ar) |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN110407703A (zh) * | 2019-08-02 | 2019-11-05 | 深圳振强生物技术有限公司 | 吲哚布芬杂质的制备方法 |
WO2023285926A1 (en) | 2021-07-12 | 2023-01-19 | Galderma Holding SA | Synthesis of chiral substituted pyrazolopyrimidine compounds |
WO2023031738A1 (en) | 2021-08-31 | 2023-03-09 | Galderma Holding SA | Novel mtor inhibitor compounds |
Family Cites Families (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7138401B2 (en) | 2003-09-18 | 2006-11-21 | Conforma Therapeutics Corporation | 2-aminopurine analogs having HSP90-inhibiting activity |
BRPI0618622A2 (pt) * | 2005-11-17 | 2011-09-06 | Osi Pharm Inc | composto, composição, e, uso de um composto |
EA201070572A1 (ru) | 2007-11-07 | 2010-12-30 | Фолдркс Фармасьютикалз, Инк. | Модуляция транспорта белков |
CA2716924A1 (en) | 2008-03-19 | 2009-09-24 | Osi Pharmaceuticals, Inc. | Mtor inhibitor salt forms |
US9295673B2 (en) | 2011-02-23 | 2016-03-29 | Intellikine Llc | Combination of mTOR inhibitors and P13-kinase inhibitors, and uses thereof |
JP6047149B2 (ja) * | 2011-05-04 | 2016-12-21 | インテリカイン, エルエルシー | 併用の医薬組成物およびその使用 |
CN103796655A (zh) * | 2011-05-06 | 2014-05-14 | 加利福尼亚大学董事会 | 多囊性疾病的治疗 |
KR20140084130A (ko) * | 2011-10-07 | 2014-07-04 | 셀좀 리미티드 | Mtor 억제제로서의 모르폴리노 치환된 바이사이클릭 피리미딘 우레아 또는 카르바메이트 유도체 |
US9174994B2 (en) | 2011-11-23 | 2015-11-03 | Intellikine, Llc | Enhanced treatment regimens using mTor inhibitors |
CA2833701A1 (en) * | 2013-11-19 | 2015-05-19 | Pharmascience Inc. | Protein kinase inhibitors |
JP7046831B2 (ja) * | 2016-04-29 | 2022-04-04 | メルク パテント ゲーエムベーハー | 有機エレクトロルミネッセンスデバイス用の材料 |
FR3075794A1 (fr) | 2017-12-21 | 2019-06-28 | Galderma Research & Development | Nouveaux composes inhibiteurs de mtor |
-
2017
- 2017-12-21 FR FR1771402A patent/FR3075795A1/fr active Pending
-
2018
- 2018-12-20 KR KR1020207020410A patent/KR20200103032A/ko not_active Application Discontinuation
- 2018-12-20 EP EP18826025.1A patent/EP3727390B1/fr active Active
- 2018-12-20 SG SG11202005868XA patent/SG11202005868XA/en unknown
- 2018-12-20 JP JP2020534447A patent/JP2021506917A/ja not_active Ceased
- 2018-12-20 IL IL275531A patent/IL275531B2/en unknown
- 2018-12-20 AU AU2018392761A patent/AU2018392761B2/en not_active Expired - Fee Related
- 2018-12-20 CN CN201880090046.3A patent/CN111918654A/zh active Pending
- 2018-12-20 BR BR112020012201-7A patent/BR112020012201A2/pt unknown
- 2018-12-20 RU RU2020123899A patent/RU2020123899A/ru unknown
- 2018-12-20 MX MX2020006436A patent/MX2020006436A/es unknown
- 2018-12-20 WO PCT/EP2018/086074 patent/WO2019122065A1/fr unknown
- 2018-12-20 CA CA3086243A patent/CA3086243A1/en active Pending
-
2020
- 2020-06-19 US US16/907,122 patent/US11518767B2/en active Active
- 2020-06-19 CL CL2020001686A patent/CL2020001686A1/es unknown
- 2020-06-21 SA SA520412289A patent/SA520412289B1/ar unknown
Also Published As
Publication number | Publication date |
---|---|
IL275531A (en) | 2020-08-31 |
WO2019122065A1 (fr) | 2019-06-27 |
AU2018392761B2 (en) | 2023-09-14 |
RU2020123899A3 (ar) | 2022-02-17 |
MX2020006436A (es) | 2020-09-17 |
AU2018392761A1 (en) | 2020-07-09 |
JP2021506917A (ja) | 2021-02-22 |
CA3086243A1 (en) | 2019-06-27 |
EP3727390A1 (fr) | 2020-10-28 |
EP3727390B1 (fr) | 2023-03-22 |
CL2020001686A1 (es) | 2020-11-27 |
SG11202005868XA (en) | 2020-07-29 |
CN111918654A (zh) | 2020-11-10 |
FR3075795A1 (fr) | 2019-06-28 |
IL275531B2 (en) | 2023-09-01 |
IL275531B1 (en) | 2023-05-01 |
KR20200103032A (ko) | 2020-09-01 |
RU2020123899A (ru) | 2022-01-21 |
US20200317683A1 (en) | 2020-10-08 |
US11518767B2 (en) | 2022-12-06 |
BR112020012201A2 (pt) | 2020-11-24 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BR112018003026A2 (pt) | composições compreendendo um inibidor de pi3k e um inibidor de hdac | |
MY196909A (en) | Boronic acid derivatives and therapeutic uses thereof | |
CY1120635T1 (el) | Βενζαμιδια αμινοετεροαρυλιου ως αναστολεις κινασης | |
CL2017002650A1 (es) | Compuestos novedosos | |
PH12017500408A1 (en) | Heteroaryl compunds as btk inhibitors and uses thereof | |
MX2021015106A (es) | Inhibidores de ferroportina novedosos. | |
MX2018002986A (es) | Compuestos de heteroarilo como inhibidores de cinasas asociadas al receptor de interleucina 1 (irak) y sus usos. | |
BR112018003812A2 (pt) | compostos de heteroarila como inibidores de irak e usos dos mesmos | |
EA201890086A1 (ru) | 1,4-замещенные производные пиперидина | |
TR201905814T4 (tr) | Jak inhibitörü olarak bipirazol tuzu. | |
MX2017014035A (es) | Formas solidas novedosas. | |
GEP201706623B (en) | Pyrrolotriazinone derivatives as pi3k inhibitors | |
EA201690129A1 (ru) | Гетероарильные соединения, пригодные в качестве ингибиторов sumo-активирующего фермента | |
SA520412289B1 (ar) | مركبات مثبط الهدف الميكانيكي للراباميسين | |
EA201591406A1 (ru) | C-19 модифицированные тритерпеноиды с ингибиторной активностью созревания вич | |
EA201890331A1 (ru) | Пиридинондикарбоксамиды для применения в качестве ингибиторов бромодомена | |
NI201500115A (es) | Estra-1,3,5(10), 16-tetraeno-3-carboxamidas para la inhibición de la 17b-hidroxiesteroide deshidrogenasa (akr1 c3) | |
EA201790016A1 (ru) | АНАЛОГ ПИРИДИНО[1,2-a]ПИРИМИДОНА, ПРИМЕНЯЕМЫЙ В КАЧЕСТВЕ ИНГИБИТОРА PI3K | |
EA201690072A1 (ru) | Состав, содержащий гиполипидемическое средство | |
MX2020003495A (es) | Derivados de acido boronico y sintesis de los mismos. | |
EA201600636A1 (ru) | 2-амино-6-метил-4,4а,5,6-тетрагидропирано[3,4-d][1,3]тиазин-8а(8н)-ил-1,3-тиазол-4-ил амиды | |
EA201792425A1 (ru) | Трициклические соединения и их применение в качестве ингибиторов фосфодиэстераз | |
PH12016501461A1 (en) | 5-biphenyl-4-heteroarylcarbonylamino-pentanoic acid derivatives as neprilysin inhibitors | |
MX2020006434A (es) | Nuevos compuestos inhibidores del blanco mecanistico de rapamicina (mtor). | |
EA201792264A1 (ru) | Способы лечения воспалительных заболеваний |